Results 141 to 150 of about 1,448,905 (180)

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy. [PDF]

open access: yesBlood Cancer J
Wang Y   +55 more
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

open access: yesJ Comp Eff Res
Kittai AS   +6 more
europepmc   +1 more source

Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. [PDF]

open access: yesInt J Mol Sci, 2021
Ziouti F   +8 more
europepmc   +1 more source

Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. [PDF]

open access: yesAging (Albany NY), 2021
Wang X   +14 more
europepmc   +1 more source

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]

open access: yesFront Oncol
Kluitmans DJF   +8 more
europepmc   +1 more source

The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice. [PDF]

open access: yesJ Allergy Clin Immunol
Arce B   +10 more
europepmc   +1 more source

Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. [PDF]

open access: yesVet Dermatol, 2020
Goodale EC   +13 more
europepmc   +1 more source

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

open access: yesHaematologica, 2016
Jennifer R. Brown   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy